Skip to main content
All Posts By

admin

Jhu fastforward

Hopkins’ FastForward aims to put research to work – Baltimore Business Journal

By News Archive

Jhu fastforward

“Research for research’s sake” is not a refrain you’ll hear from Johns Hopkins Whiting School of Engineering Dean Nicholas Jones.

Universities have been working on increasing the amount of their research being used for commercially available products and services, but in Maryland the process has been somewhat slow. While Hopkins is the most highly funded university by the National Institutes of Health, it lags behind its peers in terms of patents, new companies and other measures of commercialization.

Read More
DHHS

HHS seeks applicants for HHSentrepreneurs Program

By News Archive

DHHS

Health and Human Services (HHS) Deputy Secretary Bill Corr announced today that the Department is seeking innovators and entrepreneurs to apply for the HHSentrepreneurs Program.  Launched last year, HHSentrepreneurs connects private sector innovators and entrepreneurs with teams of federal employees working on projects that address some of the biggest challenges in health, health care and human services.

The first individuals hired last October through HHSentrepreneurs are working on critical projects including the Affordable Care Act, health resilience technology, and the nation’s organ transplant system.

“By bringing the best in the public and private sectors together, HHSentrepreneurs is creating an environment in HHS that fosters innovative solutions to new and old challenges,” Deputy Secretary Corr said.

Read More
DHHS

NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) – Grants.gov

By News Archive

DHHS

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NIAID. This program will utilize the cooperative agreement mechanism (U44) to enable support for hypothesis-driven, milestone-driven clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High-risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and can be proposed under this program. However, not more than one clinical trial should be proposed within each grant application. The NIAID has a robust infrastructure for conducting clinical studies that includes independently managed resources provided through grants and contracts, as well as resources that are integrated within existing NIAID-supported clinical trial networks. Proposed clinical trials may use NIAIDs independent infrastructure for clinical studies, however, support will not be provided for studies that propose to use dedicated resources that are part of a NIAID-supported clinical trial network. A Commercialization Plan must be included that details plans for promoting further commercialization of the intervention/product/technology to be derived from or associated with the proposed clinical trial, including plans for promoting and establishing partnerships between the SBIR Phase II awardee and third-party investors and/or strategic partners.

Read More
bhi-logo

BHI Internship Program: Positions Available

By Uncategorized

bhi-logo

BioHealth Innovation, Inc., (BHI) a non-profit organization which strives to facilitate the development of commercially viable health IT products and companies by connecting market relevant research assets to appropriate funding, management and markets, is seeking interns as part of the BHI Internship Program.

POSITION DESCRIPTION – BHI Intern

BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, is seeking highly motivated and dynamic individuals to fill internship positions at the Rockville, MD headquarters.  The BHI Internship Program offers essential experience for IT, Business, and Biohealth students in the region.  By offering a variety of projects and responsibilities to students, BHI aims to prepare interns for professional careers in the business, life sciences, healthcare and IT industries.

Read More
partnership-nyc-medcity

Guess who hooked up? NYC matchmaking contest lists startup and healthcare industry pairs | MedCity News

By News Archive

partnership-nyc-medcity

A commercialization program to match up provider, payer and pharma technology needs with willing and able healthcare startups has announced its 10 finalists. Each will receive $100,000 tied to meeting certain performance milestones. They have three to six months to work with the healthcare group they’re matched with, depending on the complexity of the program.

PILOT Health Tech NYC, developed by the New York City Economic Development Corporation and Health 2.0, is holding its demo day today at Blueprint Health’s NYC digs. The program is also supported by StartUp Health.

Read More
sea-level-annapolis

Sea level along Maryland’s shorelines could rise two feet by 2050, according to new report

By News Archive

sea-level-annapolis

A new report on sea level rise recommends that the State of Maryland should plan for a rise in sea level of as much as 2 feet by 2050. Led by the University of Maryland Center for Environmental Science, the report was prepared by a panel of scientific experts in response to Governor Martin O’Malley’s Executive Order on Climate Change and “Coast Smart” Construction. The projections are based on an assessment of the latest climate change science and federal guidelines.

“The State of Maryland is committed to taking the necessary actions to adapt to the rising sea and guard against the impacts of extreme storms,” said Governor Martin O’Malley. “In doing so, we must stay abreast of the latest climate science to ensure that we have a sound understanding of our vulnerability and are making informed decisions about how best to protect our land, infrastructure, and most importantly, the citizens of Maryland.”

Read More
startupmd-under-armour

UNDER ARMOUR® CEO Kevin Plank to Join Startup Maryland for Inaugural “Raise Your Game” Bootcamp Session

By News Archive

startupmd-under-armour

Startup Maryland (www.startupmd.org), an initiative of the UpGlobal consortium (www.up.co), today announced that UNDER ARMOUR® Founder and CEO Kevin Plank will participate as the first instructor for Raise Your Game™.   

Raise Your Game is Startup Maryland’s bootcamp initiative developed to provide the entrepreneurial community with a structured educational program and to help startup CEOs and founders understand and employ the building blocks of strong startups and startup communities.  The new twist for this bootcamp is that the sessions will be proctored/taught by experienced (often serial) entrepreneurs who are very well-recognized and respected.

Read More

NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44)

By Uncategorized

Funding Opportunity Number: PAR-13-250
Opportunity Category: Discretionary
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
CFDA Number: 93.855
93.856
Eligible Applicants Small businesses
Agency Name: HHS-NIH11
Closing Date: May 13, 2016
Award Ceiling:
Expected Number of Awards:
Creation Date: Jun 24, 2013
Funding Opportunity Description: This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NIAID. This program will utilize the cooperative agreement mechanism (U44) to enable support for hypothesis-driven, milestone-driven clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High-risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and can be proposed under this program. However, not more than one clinical trial should be proposed within each grant application. The NIAID has a robust infrastructure for conducting clinical studies that includes independently managed resources provided through grants and contracts, as well as resources that are integrated within existing NIAID-supported clinical trial networks. Proposed clinical trials may use NIAIDs independent infrastructure for clinical studies, however, support will not be provided for studies that propose to use dedicated resources that are part of a NIAID-supported clinical trial network. A Commercialization Plan must be included that details plans for promoting further commercialization of the intervention/product/technology to be derived from or associated with the proposed clinical trial, including plans for promoting and establishing partnerships between the SBIR Phase II awardee and third-party investors and/or strategic partners.

Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=236728

Read More

Revolutionary Genome Sequencing Technologies The $1000 Genome (R01)

By Uncategorized

Funding Opportunity Number: RFA-HG-13-005
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Health
CFDA Number: 93.172
Eligible Applicants State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Agency Name: HHS-NIH11
Closing Date: Oct 17, 2013
Award Ceiling: $1,000,000
Expected Number of Awards:
Creation Date: Jun 26, 2013
Funding Opportunity Description: The National Human Genome Research Institute (NHGRI) solicits R01 grant applications to develop novel technologies that will enable extremely low-cost, high quality DNA sequencing. The goal of this initiative is to reduce the cost of sequencing a mammalian-sized genome to approximately $1000. Applicants may propose to develop full-scale sequencing systems or to investigate challenges underlying key system components. Exploration of methods other than those currently being pursued as potential $1,000 genome technologies is encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=236793

Read More

Revolutionary Genome Sequencing Technologies The $1000 Genome (SBIR [R43/R44])

By Uncategorized

Funding Opportunity Number: RFA-HG-13-007
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Health
CFDA Number: 93.172
Eligible Applicants Small businesses
Agency Name: HHS-NIH11
Closing Date: Oct 17, 2013
Award Ceiling:
Expected Number of Awards:
Creation Date: Jun 26, 2013
Funding Opportunity Description: The National Human Genome Research Institute (NHGRI) solicits SBIR (R43/R44) grant applications to develop novel technologies that will enable extremely low-cost, high quality DNA sequencing. The goal of this initiative is to reduce the cost of sequencing a mammalian-sized genome to approximately $1000. Applicants may propose to develop full-scale sequencing systems or to investigate challenges underlying key system components. Exploration of methods other than those currently being pursued as potential $1,000 genome technologies is encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=236794

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.